Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Department Of Justice Announces National Enforcement Sweep Of Genetic Testing Laboratories And Telemedicine Providers

    Genetic testing and telemedicine targeting senior citizens and individuals with disabilities have been the subject of growing government scrutiny.
    United StatesCriminal Law
    Duane Morris LLP
    Duane Morris LLP
  • Article

    APHIS Seeks Comment On Draft Environmental Documents For Deregulation Of American Chestnut Developed Using Genetic Engineering

    On June 6, 2025, the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) announced that it has prepared a revised draft environmental impact statement...
    United StatesEnvironment
    Bergeson & Campbell
Bergeson & Campbell
  • Article

    Meister Records ACTEC Podcast Episode

    Julia B. Meister, head of Taft's Wealth Transfer Litigation practice, and a partner in the firm's Litigation, Private Client, and Health Care and Life Sciences practice groups...
    United StatesFamily and Matrimonial
    Taft, Stettinius & Hollister LLP
    Taft, Stettinius & Hollister LLP
  • Article

    BIO Industry Group Comments On JOBS Act

    The Biotechnology Industry Organization noted that this week marks a JOBS Act milestone with the 100th company to have gone public since the Act was passed.
    United StatesFinance and Banking
    Morrison Foerster
    Morrison Foerster
  • Article

    Fewer Checks, Bigger Stakes: Reduced Deal Volume And Shifting Terms Reshape Mid-Market Life Sciences VC In 2026

    The opening quarter of 2026 brought a noticeable cooling in mid-market life sciences venture activity, with deal volume dropping significantly from prior periods.
    United StatesFinance and Banking
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Recent Capital Markets Transactions: 2023

    Market leaders and major investment banks turn to WilmerHale for capital markets legal advice and business advantage. In 2022, we handled more than 50 public offerings, Rule 144A ...
    United StatesFinance and Banking
    WilmerHale
    WilmerHale
  • Article

    Recent Capital Markets Transactions: 2024

    Market leaders and major investment banks turn to WilmerHale for capital markets legal advice and business advantage.
    United StatesFinance and Banking
    WilmerHale
    WilmerHale
  • Video

    [Video] Biotech Financing Environment And Deal Considerations

    Against the backdrop of a prolonged global pandemic, international conflict and a shifting economic climate, the capital markets landscape is ever-changing. Cooley brings you a quarterly...
    United StatesFinance and Banking
    Cooley LLP
    Cooley LLP
  • Article

    13 Power-Player Lawyers Advising Life-Sciences Companies Through The Biotech Feeding Frenzy

    Deanne Maynard, Janet Xiao, and Stacy Cline Amin were featured in the Business Insider's coverage of lawyers helping life-sciences and biotech companies raise capital
    United StatesFood, Drugs, Healthcare, Life Sciences
    Morrison Foerster
    Morrison Foerster
  • Article

    2019 Medicare DMEPOS Fee Schedule Released

    CMS has posted calendar year 2019 Medicare fee schedule rates for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    2021 Enforcement Review: FDA-Regulated Medical Products

    While the continuing COVID-19 public health emergency remained an obstacle to many Food and Drug Administration ("FDA") inspections in 2021, the pandemic did not preclude criminal and ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    2024 Top-Of-Mind Issues For Life Sciences Companies

    As we reflect on 2023 and make predictions for 2024, it is remarkable the number of significant events occurring this past year that will be impactful for the activities of the life sciences industry...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Sheppard
    Sheppard
  • Article

    7 Tips For Biotech Companies Seeking Capital In A Volatile Market

    The article provides a recap of the 2018 market for early-stage public biotech companies...
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    A 50-State Survey Of The Heeding Presumption

    As Reed Smith attorney Jim Beck points out, there are plenty of differences in approach, from states that employ the heeding presumption, to those that recognize it in a limited capacity, and those that reject it entirely.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    A Contribution To Residents' Quality Of Life

    People with Alzheimer's and dementia often suffer from anxiety and agitation. One of the most effective means of dealing with those symptoms is therapy animals.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Lowndes
    Lowndes
  • Article

    Accord Biopharma Announces FDA Approval Of IMULDOSA (Ustekinumab-srlf)

    On October 14, 2024, Accord BioPharma, Inc. announced that the FDA has approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Adalimumab Biosimilar Wins NMPA Approval

    Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. announced that the jointly developed adalimumab biosimilar injection (Junmaikang ®) was officially approved by...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alteogen And Sandoz Enter A Biosimilars Agreement Relating To Subcutaneous Products

    Alteogen Inc. announced that it entered an exclusive license agreement with Sandoz AG pursuant to which Sandoz will have world-wide rights to use Alteogen's ALT-B4 hyaluronidase, derived using Hybrozyme™ Technology...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech And Advanz Pharma Extend Partnership To Commercialize Five Proposed Biosimilars In Europe

    Advanz Pharma ("Advanz") and Alvotech announced that they entered an exclusive partnership agreement regarding supply and commercialization of five biosimilars in Europe, with Alvotech responsible for the development and commercial supply of the biosimilars, and Advanz responsible for registration and commercialization in Europe.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech And Teva Reach Ustekinumab (STELARA) Settlement With J&J

    Alvotech and Teva Pharmaceuticals, Inc. announced that they reached a settlement and license agreement with Johnson & Johnson regarding AVT04, Alvotech's proposed biosimilar to STELARA...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Showing 361–380 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics